Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916636 | 0.85 | MDM2 (0.42) | KMT2AMEN1LMNARXFP1THRB | |
| SCHEMBL711459 | 0.85 | TP53 (0.49) | KMT2AMEN1RXFP1THRBHTR6 | |
| SCHEMBL916624 | 0.80 | PDE7A (0.40) | KMT2AMEN1LMNAALDH1A1HSP90AA1 | |
| SCHEMBL916479 | 0.78 | HTR6 (0.35) | KMT2AMEN1LMNARXFP1THRB | |
| SCHEMBL916281 | 0.75 | PDE7A (0.39) | KMT2AMEN1LMNAALDH1A1HSP90AA1 | |
| SCHEMBL917261 | 0.75 | MEN1 (0.38) | KMT2AMEN1LMNAALDH1A1HSP90AA1 | |
| SCHEMBL916099 | 0.74 | PDE7A (0.37) | KMT2AMEN1LMNAALDH1A1HSP90AA1 | |
| SCHEMBL915772 | 0.73 | KMT2A (0.45) | KMT2AMEN1LMNAALDH1A1HSP90AA1 | |
| SCHEMBL916539 | 0.73 | MAPK1 (0.44) | KMT2AMEN1LMNARXFP1THRB | |
| SCHEMBL13356972 | 0.71 | HTR6 (0.48) | RXFP1THRBHTR6TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| US-7812036-B2 | Androgens | N.V. ORGANON (NL) | 2010-10-12 | — | — | US | disclosed |
| EP-1742912-B1 | NOVEL ANDROGENS | ORGANON NV (NL) | 2010-08-25 | — | — | EP | disclosed |
| US-20070225352-A1 | Novel Androgens | PHARMACOPELA DRUG DISCOVERY, INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225352-A1 | Novel Androgens | NR5A1, AR, SHBG | KMT2A 1595/4885MEN1 326/4885LMNA 3044/4885 |
| US-20110009428-A1 | NOVEL ANDROGENS | NR5A1, AR, NR3C2 | KMT2A 3473/4885MEN1 2248/4885LMNA 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.